Vitamin E quinone Alpha-tocopherylquinone is formed during free radical attack on vitamin E and has been shown to undergo reduction by NQO1 (NAD(P)H dehydrogenase [quinone] 1) to generate vitamin E hydroquinone. Since it has been recognized that alpha-tocopherylquinone in living tissue for global assessment of antioxidative defense system. The ratio of alpha-tocopherol alpha-tocopherylquinone concentrations were increased under oxidative stress with the exception of plasma. Alpha-tocopherylquinone and a low fat diet have positive effect on a patient with chronic continuous ulcerative colitis. The patient's condition improved dramatically with both colonic and extraintestinal manifestations of the disease. Withdrawal of alpha-tocopherylquinone for periods of one to two days produced recurrence of inflammation, which was again reduced upon re-introduction of alpha-tocopherylquinone.

Pimobendan (INN, or pimobendane; tradenames Vetmedin, Acardi, and Heartmedin) is a veterinary medication. Under the trade name Acardi, it is available for human use in Japan. Usually, this medicine is used to treat acute heart failure and chronic heart failure (mild to moderate in severity). By increasing the calcium ion sensitivity to protein regulating myocardial contraction and also by inhibiting phosphodiesterase (PDE-III) activity, this medicine dilates the blood vessels and improves the symptoms of heart failure such as shortness of breath and difficulty in breathing. Pimobendan is metabolized into an active metabolite (desmethylpimobendan) by the liver. The parent compound, pimobendan, is a potent calcium sensitizer while desmethylpimobendan is a more potent phosphodiesterase III inhibitor. Pimobendan is 90–95% bound to plasma proteins in circulation. This may have implications in patients suffering from low blood protein levels (hypoproteinemia/hypoalbuminemia) and in patients that are on concurrent therapies that are also highly protein bound.